Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors

NCT ID: NCT05596344

Last Updated: 2023-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-20

Study Completion Date

2032-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was a single-center prospective, real-world observational study with plans to enroll all eligible patients. The basic information, anxiety and depression, treatment and prognosis of these patients were collected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 200 patients with malignant tumors will be enrolled in Henan Cancer Hospital. This study is a single-center prospective real-world observational study, and all eligible patients are planned to be enrolled. The basic information, anxiety and depression, treatment and prognosis of these patients were collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Tumor Anxiety Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hospital Anxiety and Depression Scale

The basic information, anxiety and depression, treatment and prognosis of these patients were collected.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women of all ages are welcome.
2. Pathological diagnosis of malignant tumor in our hospital.
3. Received at least one hospitalization at this hospital.
4. The expected survival time is greater than 1 year.

Exclusion Criteria

1.There was no pathological report of malignancy.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Henan Cancer Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wang Jiaqiang

associate chief physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Bone and Soft Tissue ,Henan Cancer Hospital

Zhengzhou, Henan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Wang Jiaqiang, Dr

Role: CONTACT

13592413731

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tian Zhichao, Dr.

Role: primary

+8618737187831

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZZUSC-16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.